DailyIQ
Last updatedUpdating…

MDT·Medtronic plc

$93.01
+0.00 (+0.00%)
High
$93.45
Open
$93.01
Market Cap
117.54B
52W High
$106.33
Low
$92.16
P. Close
$93.01
P/E
22.46
52W Low
$73.05
Fwd P/E
14.51
DailyIQ Est.
$107.32
Inst. Ownership
0.0%
Short Interest
3.17%
Days to Cover
2.7
Div. Yield
3.08%
Next Ex-Div
~Dec 25
Div. Growth
43+ yrs
Technical Score (1D)
31
BEARISH
News Sentiment
54
MIXED
On Oct 13, Medtronic closed at $93.01, rising 1.17% and outperforming the S&P 500’s slight decline. The medical‑device firm’s shares had slipped 1.99% over the past month, but the recent gain suggested a modest rebound. Analysts had projected earnings per share of $1.34, a 1.47% drop year‑over‑year. Revenue was expected to grow 5.66% to $9.47 billion. Investors were watching the upcoming earnings release for further guidance.
LOW TARGET
$85 -8.6%
2 analysts
MEAN TARGET
$104 +12.3%
19 analysts
HIGH TARGET
$121 +30.1%
15 analysts
PRICE RANGE
$85.00 - $121.00
SB / B / H / S / SS
10/13/11/1/1
DAILYIQ EST.
$107.32 (+15.4%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
Ireland
Symbol
MDT
Description
Medtronic plc is a global medical technology leader focused on developing and commercializing device-based therapies for a variety of conditions. The company's core business revolves around four key segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Medtronic's Cardiovascular portfolio offers solutions for cardiac rhythm management and structural heart disease, while its Neuroscience segment provides devices for spinal and brain therapies. The Medical Surgical segment focuses on surgical instruments and technologies, and the Diabetes segment offers insulin pumps and glucose monitoring systems. Founded in 1949, Medtronic operates internationally, providing innovative medical solutions to healthcare providers and patients worldwide.
Bought (1Y)
0 shares
$0
Sold (1Y)
97,094 shares
$8.2M
KIIL HARRY SKIPEVP & President Cardiovascular
Sell1,483 shares2026-09-16
Blomquist Denise L.Chief Accounting Officer
Gift600 shares2026-09-15
Marinaro MichaelEVP, Pres MedSurg and Americas
Tax Withholding1,084 shares2026-08-20
Martha GeoffreyChairman and CEO
Award/Grant273,150 shares2026-08-03
Martha GeoffreyChairman and CEO
Award/Grant295,002 shares2026-08-03
75/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
65.0%
Net Margin
13.2%
Revenue CAGR
6.2%
Current Ratio
2.13x
Debt / Equity
0.57x
Return on Equity
9.7%
Earnings Summary
Medtronic plc is a global medical technology leader focused on device-based therapies across cardiovascular, neuroscience, medical surgical, and diabetes segments, operating in the highly regulated medical devices sector. In the most recent quarters, Medtronic posted EPS of $1.39 in Q4 2024 and $1.62 in Q1 2025, both beating estimates of $1.36 and $1.58 respectively, while revenue rose from $8.292 billion to $8.927 billion, a 7.9% increase that outpaced prior quarter growth. The company continued to deliver positive EPS in Q2 2025 ($1.26 vs. $1.23 estimate) and Q3 2025 ($1.36 vs. $1.31 estimate), with revenue climbing to $8.961 billion, sustaining a 4.8% YoY increase. Historically, Medtronic has maintained a steady upward trajectory in revenue, with consistent beats in EPS over the past four quarters, though the 2026 Q3 EPS of $1.36 fell short of the $1.69 estimate, indicating a potential slowdown. The company’s recent news highlights a revised FY27 organic revenue growth outlook of 7.25%–7.75% and a $700 million investment in its surgical robotics platform, underscoring a strategic pivot toward technology‑enabled operating rooms.

EPS

EstBeatMiss
$1.16$1.31$1.46$1.61$1.76Q2'25Q3'25Q3'26Q4'26Q1'27Q2'27
QtrEstActual+/−
Q2'27$1.33 - -
Q1'27$1.40$1.45+3.4%
Q4'26$1.54$1.55+0.6%
Q3'26$1.69$1.36-19.5%
Q3'25$1.31$1.36+3.5%
Q2'25$1.23$1.26+2.5%

Revenue

EstBeatMiss
$8.3B$8.8B$9.2B$9.6B$10.0BQ2'25Q3'25Q3'26Q4'26Q1'27Q2'27
QtrEstActual+/−
Q2'27$9.6B - -
Q1'27$9.6B$9.8B+1.2%
Q4'26$9.7B$9.8B+0.8%
Q3'26$9.6B$9.0B-6.4%
Q3'25 - $9.0B -
Q2'25 - $8.5B -

Market Data

MDT Stock Snapshot

BEARISH31/100
$93.01+$0.00 (0.0%)
Market cap
117.54B
P/E ratio
22.5
Day range
$92.16 – $93.45
News sentiment
54/100 · Neutral
Analyst target
$104.44 (+12.3%)
Consensus
Buy · 36 analysts
52-week range+27.3% off low · -12.5% from high
$73.05$106.33
Price $93.01 DailyIQ Est. $107.32

The chart on MDT has not stabilised: price is in the middle of its 52-week range and the trend is still down. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into MDT?

RICH

At today's price, Medtronic plc needs to grow free cash flow about 5.1% a year for the next 10 years to justify its valuation at a 6.78% cost of capital. Over its actual history it has compounded free cash flow at 1.6% a year, so the market is asking for 3.5 percentage points above its own delivered rate. On that basis MDT looks priced above what its own growth record supports.

Implied FCF growth
5.1%
Historical FCF CAGR
1.6%
Growth gap
+3.5 pts
Verdict
RICH
Discount rate (WACC)
6.78%
Beta
0.58

Behaviour On Record

What MDT's own history says about today's numbers

Realized volatility (21d)
24.2% 76th pct
Below its peak
-31.0%
vs 200-day average
+5.4%
Up days (1y)
47%

Medtronic plc is currently running 24.2% annualised volatility over the last 21 sessions. Measured against MDT's own 13 years of daily returns rather than a market-wide average, that is the 76th percentile — elevated for this stock, against a typical reading of 19.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

MDT is trading -31.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.6%, and the deepest was -38.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +5.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 63rd percentile — a somewhat wider gap than its own norm. Over the past year MDT closed higher on 47% of sessions, and it is currently 5 sessions into a rising streak.

On October specifically: over 14 years of records, MDT finished the month higher 7 of 14 times, with a median return of -0.0% and an average of +0.3%. Its strongest month historically has been January at +3.1% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: MDT has opened more than 2% away from the prior close in 58 of 3,268 sessions (1.8% of the time), with the largest gaps running +6.3% and -6.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, MDT moved an average of 2.2% in the session after earnings, closing higher 3 of those 3 times, with a median move of +1.6% and a largest of +5.1%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against MDT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of MDT's sector?

Medtronic plc sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, MDT ranks 3rd of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#3 of 15

Options Market

What is the options market pricing for MDT?

CallsPuts

For Medtronic plc's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.41), with at-the-money implied volatility around 51.3%. The options market is pricing roughly a ±3.2% move by that expiry — a range of about $89.94–$95.92.

Put/call ratio (2026-10-16)
0.41
ATM implied volatility
51.3%
Total open interest
96,225
Expected move by 2026-10-16
±3.2% ($89.94–$95.92)

Analyst Rating Changes

Are analysts turning bullish or bearish on MDT?

BTIG most recently reiterated its rating on Medtronic plc to Buy on Oct 12, 2026 with a price target of $99 (from $100). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
BTIG — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$100 → $99
Oct 7, 2026BarclaysInitiatedEqual-Weight$95
Sep 30, 2026TD CowenReiteratedBuy$110
Sep 3, 2026UBSMaintainedBuy$100 → $110
Sep 2, 2026Truist SecuritiesReiteratedHold$86 → $99
Sep 2, 2026Wells FargoMaintainedOverweight$102 → $104
Sep 2, 2026RBC CapitalReiteratedOutperform$118
Sep 2, 2026B of A SecuritiesMaintainedBuy$95 → $110
Sep 2, 2026StifelMaintainedHold$80 → $95
Sep 2, 2026BairdMaintainedNeutral$91 → $100
Sep 1, 2026BTIGMaintainedBuy$91 → $100
Sep 1, 2026NeedhamReiteratedBuy$114

Peers & ETF holders

MDT peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

54/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Medtronic closed at $93.01 on Oct 13, outperforming the S&P 500’s slight decline. The medical‑device firm’s shares had slipped 1.99% over the past month, but the recent gain suggests a modest rebound. Analysts expect EPS of $1.34, a 1.47% drop YoY, while revenue is projected to rise 5.66% to $9.47 billion. Investors are watching the upcoming earnings release for further guidance.
What did this article say?
The release outlines a projected 17% CAGR for the global bioelectronic medicine device market through 2030, highlighting Medtronic alongside competitors such as Abbott, Boston Scientific, and LivaNova. It emphasizes the advancement of closed‑loop neurostimulation technologies as a key driver of market expansion. No specific guidance, product launch, or financial impact for Medtronic is disclosed, leaving the outlook neutral for the company.
What did this article say?
During a Mad Money episode on October 7, Jim Cramer noted that Medtronic retained about 90 % of MiniMed after its IPO and later completed a separation through an exchange offer. He stated a personal preference for Medtronic while expressing dislike for MiniMed. The commentary highlighted Medtronic’s continued prominence in the healthcare equipment sector and its ranking among top stocks by hedge funds. No immediate financial or operational changes for Medtronic were announced. The remarks reflect a qualitative view rather than a material event.
What did this article say?
Medtronic plc (MDT) has outpaced the broader market by declining only 7% over the past year, while the market gained 17%. Analysts noted that the company’s valuation has become more attractive relative to its peers. The firm’s guidance now reflects a modest but improving growth outlook, driven by stronger demand in its cardiovascular and diabetes segments. This shift suggests a potential upside for investors seeking exposure to a well‑capitalized medical device player.
What did this article say?
Medtronic reported a 35.8% return over the past three years, yet recent share price softness prompted analysts to question whether its cash flows can sustain the current valuation. The company’s significant capital outlays on robotics, cardiac ablation, and the planned MiniMed diabetes split are expected to reshape growth expectations and margin profiles. These investments may delay the realization of cash flow benefits, creating uncertainty about the durability of shareholder returns. The market’s cautious stance reflects concerns that the current price may be overvalued relative to the company’s near‑term earnings prospects.
What did this article say?
In early October 2026, Medtronic disclosed new clinical data for its Altaviva tibial neuromodulation device and announced that both Altaviva and the Symplicity Spyral renal denervation system would receive Category I CPT codes effective January 2028. The company also revealed leadership changes in its Cardiac Ablation Solutions division and finalized the exchange ratio for the MiniMed spin‑off. These developments signal a strategic shift toward higher‑growth procedural therapies across cardiovascular and pelvic health, potentially boosting adoption rates and improving the earnings mix. The updates are viewed as a positive catalyst for Medtronic’s long‑term growth trajectory, though the magnitude of impact remains moderate.
What did this article say?
Medtronic announced a $700 million commitment to its surgical robotics platform, underscoring a strategic shift toward technology‑led operating rooms. The company also released its 2026 Impact Report, outlining progress on AI‑powered healthcare tools, workforce expansion, and environmental targets. This investment positions Medtronic to capture growing demand for digital health solutions and reinforces its competitive stance in the medtech sector.
What did this article say?
Medtronic reported robust financials and an updated guidance that underscored a favorable outlook for the company. The firm highlighted accelerated growth in its Cardiac Ablation Solutions segment and emphasized strategic collaborations aimed at expanding its advanced systems portfolio. Management reiterated its ambition to evolve into a multi‑platform powerhouse, positioning the company for continued growth across its core and emerging business lines.
What did this article say?
Medtronic (MDT) raised its dividend for the 49th consecutive year in June, moving closer to Dividend King status. However, the company’s stock has fallen 31% over the past five years, and its fiscal 2023 and 2024 earnings per share declined due to supply‑chain constraints, inflation, foreign‑exchange headwinds, and a sluggish recovery in elective procedures. Regulatory hurdles for its diabetes unit and increased competition, including quality‑control issues and the rise of GLP‑1 drugs, further pressured performance. The dividend increase offers an income opportunity, but the underlying operational challenges temper the upside.
What did this article say?
Medtronic plc announced the final exchange ratio of 4.5939 for its split‑off of MiniMed Group, Inc., allowing holders of Medtronic ordinary shares to exchange them for MiniMed common stock. The offer covers up to 225,361,295 MiniMed shares, with an additional 27,452,053 shares available if the offer is oversubscribed. The transaction does not extend the exchange period and is intended to complete the separation of MiniMed from Medtronic’s core operations. The move is a structural corporate action that is unlikely to materially affect Medtronic’s financials or market valuation in the short term.

Technical Analysis

Real-time indicators across multiple timeframes

31
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
5 tracked managers · $28.45M combined position · 2 adding, 3 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Schonfeld Strategic Advisors LLC▲ Buy325,2700.03%$25.45M2026-08-14
Ancora Advisors LLC▲ Buy38,4160.00%$3.01M2026-08-14
Graham Capital Management, L.P.▼ Sold out00.00%$02026-08-14
Winton Group Ltd▼ Sold out00.00%$02026-08-07
Brevan Howard Capital Management LP▼ Sold out00.00%$02026-08-14
Q2 2026 flow:305.3K sh bought ($23.88M)175.1K sh sold ($15.17M)net +130.2K sh (+$8.71M)
Congressional Trading Activity
25 disclosed trades · ~$623.5K est. traded value · 6 buys, 19 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$15K - $50K2026-08-242026-09-01
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-07-302026-08-14
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-05-152026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Kevin HernHouseOK01▼ Sell$15K - $50K2026-03-202026-04-03
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2025-11-052025-12-09
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-082025-06-22
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-05-072026-08-05
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
George WhitesidesHouseCA27▼ Sell$50K - $100K2025-03-242025-04-23
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-03-202025-04-16
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-042025-04-16
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Emily RandallHouseWA06▼ Sell$1K - $15K2025-01-062025-02-11
Tommy TubervilleSenateAL▼ Sell$15K - $50K2024-08-262026-08-05
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2024-02-092024-03-15
Pete RickettsSenateNE▼ Sell$50K - $100K2023-09-212023-10-20
Tina SmithSenateMN▼ Sell$100K - $250K2023-04-052023-04-19
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2023-03-152025-09-17
Dan SullivanSenateAK▼ Sell$1K - $15K2022-11-302023-07-26
Tommy TubervilleSenateAL▼ Sell$15K - $50K2022-01-212022-02-14